Analysts have been busy running the rule over a number of popular ASX shares.
But what are they saying about them? Let's find out if analysts are bullish or bearish, courtesy of The Bull. Here's what you need to know:
Image source: Getty Images
Downer EDI Ltd (ASX: DOW)
Baker Young reckons that investors should be selling this integrated services provider's shares this week.
The broker highlights that its current valuation leaves little margin for error and poses meaningful downside risk should trading conditions soften. It said:
Downer provides integrated services that maintains infrastructure across Australia and New Zealand. It's benefited from highly supportive macroeconomic conditions and favourable government infrastructure spending during the past two years. The company's first half result in fiscal year 2026 highlighted statutory net profit after tax of $98 million, up 29.8 per cent on the prior corresponding period.
Management expects further margin expansion through fiscal years 2026 and 2027. However, the share price increase has far outpaced underlying earnings growth. At current valuation levels, we see limited margin for error and little valuation support should conditions soften. Consequently, we believe it's prudent to take profits.
Nuix Ltd (ASX: NXL)
Another ASX share that has been named as a sell is investigative and analytics software provider Nuix.
Peak Asset Management thinks that its shares are fully valued now and that investors should be taking profit. Talking about the tech stock, it said:
Nuix is an investigative analytics software provider. It enables customers to process and search large data sets of unstructured information, including emails, documents and communications records. The company earns most of its revenue from licence and maintenance fees. Revenue of $121.2 million in the first half of fiscal year 2026 was up 15.2 per cent on the prior corresponding period.
Annualised contract value of $234.4 million was up 8.4 per cent. Investors may want to consider taking a profit as we believe gains are priced in following the half year result. We see limited scope for upside amid increasing competition.
ResMed Inc. (ASX: RMD)
Over at Securities Vault, its analysts think this sleep disorder treatment company's shares are a hold.
It is a big fan of ResMed but feels its shares are fully valued at current levels and recommends waiting for a better entry point. It said:
ResMed remains a global leader in sleep apnoea devices and digital health monitoring. Structural demand drivers, including ageing populations, increasing diagnosis rates and broader awareness of sleep health, continue to support long term growth. However, a strong share price recovery following concerns about the impact of weight loss drugs on sleep apnoea treatment appears to leave much of the near-term optimism priced into the stock.
While the company's fundamentals remain robust, the valuation reflects its market leadership and growth outlook. Investors may prefer to retain existing positions, while awaiting further earnings expansion, or more attractive entry points.
